Concepedia

Elizabeth Till

ET

Statistics

Publications

3

Citations

270

H-Index

3

Active since

2006

Affiliations

Dartmouth–Hitchcock Medical Center(Current)

Astellas Pharma (United States)

Moffitt Cancer Center

Elizabeth Till is an author at Dartmouth–Hitchcock Medical Center specializing in pharmacology, cancer pharmacology, and maximum tolerated effect.

Publications per year

2006–2008

3

Publications

3

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Anthony W. Tolcher, Alain C. Mita, Lionel D. Lewis et al. · Journal of Clinical Oncology · 2008 · 239 citations · Full text

, , +17

A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors

A. W. Tolcher, S. Antonia, Lionel D. Lewis et al. · Journal of Clinical Oncology · 2006 · 21 citations

, , +17

640 POSTER Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors

Jordi Rodón, Elizabeth Till, A. Patnaik et al. · European Journal of Cancer Supplements · 2006 · 10 citations

, , +11

1–3 of 3